FLORHAM PARK

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
Vonoprazan/amoxicillin, Table, FDA, DTC, Pharmacy, Gastrointestinal disease, NERD, NDA, Hercules, Amazon Prime Video, Food, Research, Webcast, Business, Forecasting, Prescription, Cigna, PPI, PDUFA, Tablet, Patient, Physician, Ratio, Enzyme inhibitor, DDW, Marketing, Vonoprazan/amoxicillin/clarithromycin, Heartburn, Hulu, GERD, Clinical trial, GAAP, Growth, Overalls, Eosinophilic esophagitis, Pharmaceutical industry

ET

Key Points: 
  • ET
    FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.
  • A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.
  • Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Three BASF women in manufacturing honored at the 2024 Women MAKE Awards

Retrieved on: 
Thursday, May 9, 2024
MAKE, Workforce, BASF, Woman, Safety, Female, Nursing

FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Three BASF leaders in manufacturing were among 130 women recognized nationally at The Manufacturing Institute’s (MI) annual Women MAKE Awards.

Key Points: 
  • FLORHAM PARK, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Three BASF leaders in manufacturing were among 130 women recognized nationally at The Manufacturing Institute’s (MI) annual Women MAKE Awards.
  • BASF’s 2024 award winners include:
    “Congratulations to our BASF honorees and emerging leader recognized at the 2024 Women MAKE awards.
  • Women MAKE America aims to create a 21st-century manufacturing workforce by empowering and inspiring women in the industry.
  • For more information about BASF careers and efforts that promote women in manufacturing, visit www.basf.us/women .

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

Retrieved on: 
Friday, May 3, 2024
University, Research and development, Radiation, Oncology, Research, Abstract, Immunotherapy, MD, University School, Cayetano Heredia University, Internet, Lung cancer, Radiation therapy, Johns Hopkins Hospital, International Association, Respiratory disease, Society, Lung, MD Anderson Cancer Center, Publication, Biomarker, Research institute, Esophageal cancer, Therapy, Cancer

The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.

Key Points: 
  • The conference call and webinar will feature presentations by Key Opinion Leaders (KOLs) Trevor M. Feinstein, M.D.
  • (MD Anderson Cancer Center), who will discuss below topics:
    Also featured will be a management discussion on technology platform and pipeline updates of SEED Therapeutics, BeyondSpring’s majority-owned molecular glue subsidiary.
  • He joined Piedmont Cancer Institute in 2011 and is the Director of Research at Piedmont Fayette Hospital.
  • Dr. Lin runs a translational research team that evaluates biomarkers for treatment response and disease outcomes after cancer therapy.

Chemovator invests in Detroit-based startup Heartland rethinking plastics using natural fiber reinforcements

Retrieved on: 
Thursday, May 2, 2024
Elevate, Geography, BASF, Partnership, Chemical industry, Carbon, Farmer, Plastic

Heartland works with local farmers to produce natural fiber materials, enabling manufacturers to create more sustainable products.

Key Points: 
  • Heartland works with local farmers to produce natural fiber materials, enabling manufacturers to create more sustainable products.
  • DETROIT and MANNHEIM, Germany, May 02, 2024 (GLOBE NEWSWIRE) -- Chemovator, the business incubator and early-stage investor of BASF, has successfully finalized an investment in Heartland.
  • The Detroit-based startup is a frontrunner in the production of natural fiber plastic additives, and the latest addition to Chemovator's external-facing Elevate program.
  • The monetary and strategic support provided by Chemovator enables Heartland to deepen valuable collaborations within BASF.

BASF and University of California, Berkeley, celebrate their successful 10-year collaboration

Retrieved on: 
Tuesday, April 23, 2024
Stanford University, University of Southern California, University, University of California, Irvine, BASF, Research, Partnership, University of California, History, AFL–CIO, Patent, Chemistry, University of California, Berkeley, Ministry of Energy, Associate, UC, California Institute of Technology

The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.

Key Points: 
  • The multidisciplinary research center is focused on evaluating new materials, technologies and processes that will help address key sustainability challenges.
  • To mark the anniversary, BASF and CARA hosted a scientific symposium on sustainable transformation in chemistry on April 22.
  • Since 2014, the collaboration has expanded to 11 California universities, including UC Santa Barbara, UC Irvine as well as Stanford University, California Institute of Technology, and University of Southern California.
  • More than 80 faculty members and 170 postdocs/graduate students have worked with BASF and CARA, and BASF has hired 11 postdocs/students from the CARA community.

Celularity Inc. to Host Investor and Analyst Research & Development Day

Retrieved on: 
Monday, April 22, 2024
CELU, Research, Growth, Mobile phone

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day.

Key Points: 
  • FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research & Development (R&D) Day.
  • The Investor and R&D Day, scheduled for Tuesday, May 21, 2024, from 12:00 p.m. to 4:00 p.m.
  • The event will feature members of Celularity’s executive management team, including:
    A live webcast of the Investor and Analyst R&D Day can be accessed by visiting the Investor Relations section of Celularity's website at www.celularity.com .
  • “We are very excited to host our first on-site and virtual Investor and Analyst R&D Day at our world-class headquarters, research, and manufacturing center.

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Retrieved on: 
Friday, April 19, 2024
CELU, Annual report, Security (finance), Regenerative medicine, Calendar

Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.

Key Points: 
  • Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW,” respectively.
  • The Company intends to submit a plan to Nasdaq within the 60-day period and will evaluate available options to regain compliance within the compliance period.
  • However, there can be no assurance that the Company will regain compliance within the compliance period, or maintain compliance with the other Nasdaq listing requirements.
  • The Company is working diligently to file its Annual Report on Form 10-K and will provide an update once more information is available.

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Retrieved on: 
Thursday, April 18, 2024
USD, Mayo Clinic, CELU, Management, CTM, DSM-IV codes, Conference, Development, Engineering, Clinical professor, UCM, Patient, Extracellular matrix, Healing, Regenerative medicine, Regeneration, Therapy

The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”

Key Points: 
  • The conference theme is “Mechanism to Therapy - Emerging Technologies and Therapeutic Outcomes.”
    Celularity’s abstract explores the application of various decellularized placental biomaterials, including connective tissue matrix (CTM) and umbilical cord matrix (UCM), in tendon management, both in vitro and in vivo.
  • The abstract focuses on assessing the biomaterials’ biomechanical properties, immunomodulatory effects, and preclinical outcomes in clinically relevant models to advance their potential in tendon repair.
  • I am very excited about the growing opportunity and potential of our decellularized placental biomaterials in tendon management and healing.
  • These data indicate that human placental decellularized biomaterials may represent a promising matrix suitable for tendon management and healing.

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Retrieved on: 
Monday, April 15, 2024
Pelvis, Burns, Umbilical cord, Tissue, CELU, Extremities, Form, Environment, Extracellular matrix, Good manufacturing practice, Regenerative medicine, Growth, Medical imaging

FLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”) a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February for its advanced biomaterial products and biobanking businesses.

Key Points: 
  • Celularity’s predecessor company was an early innovator in the field of placental-derived biomaterials, and today we continue to develop innovative, next-generation products in this technology.
  • Under the plan implemented, senior executives are foregoing a portion of their 2024 cash salary as well as payment in cash of any performance bonus payable in 2024.
  • Celularity’s advanced biomaterial product pipeline consists of four commercial-stage products and three investigational products.
  • Interfyl®, a decellularized human placental connective tissue matrix designed for use to replace or supplement damaged or inadequate integumental tissue.

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Retrieved on: 
Monday, April 8, 2024
CELU, Notifiable disease, Cell, Inflammation, Tissue, Gene, Cancer, SASP, Ageing, Society, Heart, NK, Annual general meeting, Vaccine

The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.

Key Points: 
  • The preclinical data, which suggest that Celularity’s placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.
  • Senescent cells are key drivers in the process of age-related cellular corruption at the heart of degenerative diseases, cancer and immuno-senescence (the progressive decline in immune function that occurs with age).
  • Moreover, if not eliminated, these cells impair the normal regenerative process that restores function to organs and tissues.
  • Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells.